PersevERA Trial

This clinical trial is investigating the efficacy and safety of GDC-9545 combined with palbociclib compared with Letrozole combined with palbocilicb in patients with oestrogen receptor positive, HER2-negative, locally advanced or metastatic breast cancer.

Who is the trial for? Women or men with confirmed hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer. Patients must have progressed greater than 12 months after completing adjuvant treatment with endocrine therapy. They should also have no serious medical conditions and a life expectancy of greater than six months. It does include patients with bone-only disease. Auckland City Hospital and Waikato Hospital are New Zealand sites for this trial.

View this link for full trial information.

Please consult with your doctor or medical team if you are interested in participating in this trial.

21 May 2021